Germano lands spot on The Medicines Company’s board

Geno Germano
The Medicines Company hopes to tap into Germano's cardiovascular disease experience.

The Medicines Company has tweaked its board, bringing former Pfizer executive Geno Germano in as an independent director and expanding Fred Eshelman’s role. Germano takes up the position 8 months after a shift in focus at Intrexon led him to give up the president post at the synthetic biology company.

Germano brings 30 years of biopharma experience to The Medicines Company. The most recent fraction of that experience he gained at Intrexon. But Germano is best known for his time at Pfizer, where he worked on cardiovascular programs that give him a background relevant to The Medicines Company’s plans.  

“Geno’s more than three decades of experience in leading global biopharmaceutical businesses and, in particular, his deep knowledge of the cholesterol lowering market gained during his tenure as group president of Pfizer’s global innovative pharma business, perfectly align with The Medicines Company’s go-forward, key operating imperatives,” Eshelman said in a statement.


Lipid-based Formulations for Early Stage Clinical Trials

Liquid-filled capsule technology has a proven record for addressing complex API formulation challenges, but also offers a simple and effective pathway to the clinic. Register now to learn more about lipid-based formulations.

The position is the second spot on a board of directors Germano has taken up since parting ways with Intrexon in March. Germano took up the first of those positions in May, when Biogen spinout Bioverativ unveiled him as a new member of its board of directors.

RELATED: Change in direction at Intrexon has Germano heading for the exit

Germano’s arrival at The Medicines Company coincides with the expansion of Eshelman’s role. The Medicines Company named Eshelman chairman in 2015—ending the 14-year reign of CEO Clive Meanwell, M.D., Ph.D.—and has now added the prefix “executive” to his title. 

The change gives Eshelman, who ran leading CRO PPD for years, a bigger role in the strategy and operation of The Medicines Company at a time when it is cutting its headcount, working to offload its infectious disease business and quickly advance its inclisiran LDL-C lowering phase 3 program.   

Meanwell will now report to Eshelman.

Suggested Articles

The action will see Kiadis switch its attention to earlier-stage natural killer cell therapies against solid tumors and hematological cancers.

The Weill Family Foundation is stumping up $106 million to create a so-called “Neurohub.”

The takeover centers on TRPML1 agonists designed to treat neurodegenerative disorders by clearing toxic proteins from the brain.